-transparent.png){kind=logo}
Carcinoid syndrome causes substantial morbidity and reduces quality of life and survival. In a recent clinical trial, 97% of patients reported bowel movement-related issues, abdominal pain, flushing, and low energy. Combining somatostatin analogs with elotristat ethyl provides a new option for managing refractory CS symptoms. Health care providers should consider strategies that take advantage of approved dosing for patients with CS-related diarrhea.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Richard Cook, and
Andrew E Hendifar
September 2019,
Pancreas,
Richard Cook, and
Andrew E Hendifar
January 2018,
The American journal of managed care,
Richard Cook, and
Andrew E Hendifar
March 2010,
Indian pediatrics,
Richard Cook, and
Andrew E Hendifar
January 2015,
Jornal de pediatria,
Richard Cook, and
Andrew E Hendifar
December 2003,
The Psychiatric clinics of North America,
Richard Cook, and
Andrew E Hendifar
January 2013,
International journal of health care quality assurance,
Richard Cook, and
Andrew E Hendifar
January 2019,
Journal of the advanced practitioner in oncology,
Richard Cook, and
Andrew E Hendifar
January 1980,
Annals of internal medicine,
Richard Cook, and
Andrew E Hendifar
March 2005,
Ear, nose, & throat journal,
Richard Cook, and
Andrew E Hendifar
January 2017,
Journal of doctoral nursing practice,
